Intermediate-high risk pulmonary embolism: When teamwork really matters

Q4 Medicine
Bibi Ayesha Bassa , Elizabeth Little , Izak Loftus , Leah Flanagan , Andrew Neil , Tomás Breslin , Cian McDermott
{"title":"Intermediate-high risk pulmonary embolism: When teamwork really matters","authors":"Bibi Ayesha Bassa ,&nbsp;Elizabeth Little ,&nbsp;Izak Loftus ,&nbsp;Leah Flanagan ,&nbsp;Andrew Neil ,&nbsp;Tomás Breslin ,&nbsp;Cian McDermott","doi":"10.1016/j.tru.2023.100157","DOIUrl":null,"url":null,"abstract":"<div><p>Pulmonary embolism is a common disease associated with significant morbidity and mortality. Existing validated risk stratification tools have enabled the rapid identification of patients with low versus high-risk pulmonary embolism. Intermediate-high risk pulmonary embolism is defined as pulmonary embolism with haemodynamic stability, evidence of right ventricular dysfunction and elevated cardiac biomarkers. The therapeutic management of intermediate-high risk pulmonary embolism in the acute setting is challenging as these patients are often unwell, but do not fulfil criteria for high-risk pulmonary embolism. Although current guidelines recommend prompt first-line treatment with systemic anticoagulation and monitoring for deterioration, alternative strategies are being increasingly considered in this cohort. These include systemic or catheter-directed thrombolysis, surgical embolectomy, and mechanical circulatory support. In this case series, we discuss three cases of intermediate-high risk pulmonary embolism with a focus on multidisciplinary decision making in clinical management. Following on from this, we provide a brief narrative review of the current literature and guidelines surrounding this topic, considering the risks and benefits of alternative therapy options on patient outcomes.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572723000287/pdfft?md5=fbf25e90a59089099db2532c45a0e508&pid=1-s2.0-S2666572723000287-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572723000287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Pulmonary embolism is a common disease associated with significant morbidity and mortality. Existing validated risk stratification tools have enabled the rapid identification of patients with low versus high-risk pulmonary embolism. Intermediate-high risk pulmonary embolism is defined as pulmonary embolism with haemodynamic stability, evidence of right ventricular dysfunction and elevated cardiac biomarkers. The therapeutic management of intermediate-high risk pulmonary embolism in the acute setting is challenging as these patients are often unwell, but do not fulfil criteria for high-risk pulmonary embolism. Although current guidelines recommend prompt first-line treatment with systemic anticoagulation and monitoring for deterioration, alternative strategies are being increasingly considered in this cohort. These include systemic or catheter-directed thrombolysis, surgical embolectomy, and mechanical circulatory support. In this case series, we discuss three cases of intermediate-high risk pulmonary embolism with a focus on multidisciplinary decision making in clinical management. Following on from this, we provide a brief narrative review of the current literature and guidelines surrounding this topic, considering the risks and benefits of alternative therapy options on patient outcomes.

中高风险肺栓塞:团队合作真的很重要
肺栓塞是一种常见疾病,发病率和死亡率都很高。现有的有效风险分层工具能够快速识别低危和高危肺栓塞患者。中高风险肺栓塞被定义为血流动力学稳定、有右心室功能障碍和心脏生物标志物升高证据的肺栓塞。急性期中高风险肺栓塞的治疗管理具有挑战性,因为这些患者通常身体不适,但不符合高风险肺栓塞的标准。尽管目前的指南建议及时进行全身抗凝一线治疗并监测病情恶化,但越来越多的人开始考虑对这类患者采取其他治疗策略。这些策略包括全身或导管引导溶栓、外科栓子切除术和机械循环支持。在本病例系列中,我们讨论了三例中高危肺栓塞病例,重点是临床管理中的多学科决策。在此基础上,我们简要回顾了围绕这一主题的现有文献和指南,并考虑了替代疗法对患者预后的风险和益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信